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PREFACE 
 The overall incidence of esophageal cancer and gastric cancer is 
increasing. The vast majority of these cancers have inactivation of the 
p53 and p16 genes at an early stage followed by defects in genes such as 
Apc, Rb and Cyclin D, at later stages of progression. 
 There is also mounting evidence that numerous, specific regions 
throughout the genome are frequently lost in these cancers. The study of 
the p53 tumor suppressor gene has blossomed into a field of its own. 
With the abundance and intensity of research continuing in the field of 
molecular biology on carcinogenesis, we begin to understand the 
importance of p53 tumor suppressor in human cells. 
 The accumulating knowledge about the inactivation of the p53 
tumor suppressor gene could ultimately provide us with objective 
diagnostic tools, more accurate markers for prediction of malignant 
transformation from premalignant epithelium and facilitate the 
introduction of novel therapeutic options for the management of 
esophageal and stomach cancers. 
 
  1
INTRODUCTION 
 Esophageal cancer may develop as either squamous cell cancer or 
adenocarinoma. Squamous cell carcinoma is the predominant subtype of 
esophageal cancer worldwide. It is the third most common gastro 
intestinal malignancy. Incidence in India is between 10 to 50 in 1,00,000 
individuals. Though cure is possible when detected early, most often it is 
advanced at the time of presentation. 
 Gastric Cancer remains second only to lung cancer as a leading 
cause of cancer mortality worldwide. Adenocarcinoma of the cardia and 
GE junction appears to have increased in the past two decades. The 
incidence of intestinal type gastric cancer is increasing whereas that of 
diffuse type has remained constant overtime. There is a consistent 
predominance of gastric cancer in males, worldwide (2 : 1 male : female 
ratio). Most cases of the disease present at advanced stages and effective 
therapy is limited. 
 Survival rates are dismal even in the best of centres. Five year 
survival rates ranges between 5-12% according to the International 
Tumour Registry. 75% of the therapy is palliative and less than a fifth of 
patients with gross tumor resection survive more than 5 years. 
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 The present multimodality therapy is showing encouraging results 
in mortality but the morbidity of undergoing it remains very high. Hence 
these epidemiologic variables provoke intense efforts to identify new 
features in depth and strategies of molecular biology for better 
understanding the pathogenesis and / or management of esophageal and 
gastric malignancies (3). 
 Human esophageal carcinogenesis is a multi stage progressive 
process which involves the conversion of normal epithelium to that with 
Basal cell hyperplasia, dysplasia or carcinoma in situ and then to invasive 
squamous cell carcinoma (SCC) (11-15). 
 Development of intestinal type of gastric cancer is probably a 
multi-step process whereas it remains tentative whether the diffuse type 
of malignancy follows an analogous progression. Hence the intestinal 
type comprise gastric mucosal metaplasia - dysplasia - carcinoma 
sequence. 
The accumulation of multiple genetic alterations leading to  
(1) Oncogene over expression 
(2) Tumor suppressor loss and 
(3) Defective DNA mismatch repair 
is associated with malignancies of esophagus and stomach. 
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 The gene that has garnered the most attention is the tumor 
suppressor p53. The most frequent genetic abnormalities found in these 
cancers tend to be loss of Heterozygosity (LoH) of TSG. Early studies 
reported that LoH (60-70%) and mutations (38-71%) of p53 gene are 
quite frequent. In addition, p53 mutations are also observed  in intestinal 
metaplasia (38%) and gastric dysplasia (58%) suggesting that p53 
mutations may be an early event in carcinogenesis. 
 p53 gene product regulates cell-cycle progression, DNA repair, 
apoptosis and neo-vascularisation in normal and malignant tissue via 
highly complex DNA and protein interactions. 
 Studies have shown that restoration of p53 expression by gene 
therapy techniques results in cell cycle arrest and apoptosis as well as 
enhanced sensitivity to chemotherapy and radio-therapy in esophageal 
and gastric cancer cells. 
 In this study we have experimentally identified the presence of 
mutant p53 status in esophageal and gastric cancer patients. 
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TUMOUR SUPPRESSOR  GENE --  p53 
 Cell cycle is a term used to describe the orderly sequence of events 
which ensure the faithful duplication of all the cellular components in 
their correct sequence and partitioning of these components into daughter 
cells. 
 Two classes of genes and their protein products are employed for 
this process  
           (1) genes whose products are obligatory for progress through the 
cell cycle G1 to S  –  to G2 to M phases and 
 (2) genes whose proteins act as checkpoints and stop the 
progression through the cell cycle if conditions are not satisfactory. 
 The crucial differences between normal cell and cancer cells stem 
from discrete changes in specific genes controlling proliferation and 
tissue homeostasis. 
 p53 gene have become the centre of intensive study because 
slightly more than 60% of human cancers contain mutations in this gene. 
p53 gene was originally discovered in 1979 by Arnold Levine of 
Princeton University, David Lane of the University of Dundee, Scotland 
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and William old of the memorial sloan - kettering cancer centre in New 
York City (5, 6, 17). 
 In 1989, Bert Vogelstein, Ray white and their colleagues showed 
that p53 is actually a tumor suppressor. Since then mutant forms of p53 
have cropped up in so many tumors and aroused so much interest that 
science hailed the p53 protein as the "Molecule of the Year" in 1993. 
 p53 is located at chromosome  region 17 p13. Normally, in a cell 
the p53 protein is kept at low concentration by its relatively short half life 
of about 20 minutes. DNA damage, hypoxia and fall in ribonucleoside 
triphosphate pools below a critical threshold will results in rapid increase 
in the level of p53 in the cell and activation of p53 as a transcription 
factor (11, 17). This activated p53 acts to stop cell division by cell cycle 
arrest thus giving the cell a chance to repair the DNA before the errors are 
duplicated and passed on to daughter cells or initiate apoptosis if the 
damage is irreparable. But when mutated, it loses its protective function 
which allows mutations to accumulate in other genes and leads to more 
than 60 percent of all human cancers including cancers of esophagus, 
stomach, colon, lungs, bladder, brain and liver (9, 10, 21). 
 Immunohistochemistry (IHC) detects the presence of mutant p53 in 
the tumor cells (29). Presence of immunoreactive p53 correlates the 
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presence of p53 mutation especially when the percentage of immuno-
reactive cells exceeds 10-20% (12). 
 This is because transcription of mutated p53 gene usually results in 
the production of a protein that is more stable than the wild type and 
therefore it accumulates in the nucleus, which can be detected by  
IHC (32). 
 There have been a plethora of studies correlating p53 IHC with 
clinicopathologic parameters in a variety of cancers. In head and neck 
squamous cancers presence of abnormal p53 expression correlates with 
an increased risk of loco-regional recurrence, resistance to radiotherapy, 
and risk of developing a second primary tumor. 
 Nuclear accumulation of aberrant p53 is an independent indicator 
of poor prognosis (36). Similarly, in invasive breast cancers, aberrant p53 
is associated with many aggressive biological factors and poor clinical 
outcome. Finally in melanoma, p53 expression is associated with an 
increase in the depth of invasion in the primary tumor, and the presence 
of metastatic disease. These, and other studies have convincingly 
validated the use of p53 IHC as a reliable assay for prognostication 
purposes (25). 
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In brief 
Expression 
 The p53 protein is located in the nucleus and is very labile. Agents 
which damage DNA, induce p53 to become very stable by a post-
translational mechanism, allowing its concentration in the nucleus to 
increase dramatically. 
Cellular Functions  
 Causes cell cycle arrest in response to DNA damage thereby allowing 
DNA repair and hence prevents the transmission of damaged genetic 
information to next generation. 
 Initiate apoptosis if the cell damage is severe and so loss of p53 
function is a key step in the neoplastic cascade. 
 Often as a tumor suppressor : p53 mutations can cause cells to become 
oncogenically transformed (33). 
 p53 may play a role in monitoring developmental factor dependence, 
in the  haematopoietic systems. 
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 p53 can also initiate apoptosis in response to the expression of a viral 
or cellular oncogene or the absence of a critical tumor suppressor gene 
product (Rb). 
 In addition to p53 mutations, some tumors inactivate p53 by the 
amplification of the MDM2 gene or by the localisation of p53 in the 
cell cytoplasm. 
 Humans who are heterozygous for wild type allele of p53 develop 
cancer with a very high frequency (> 90-95%) and often at an early 
age. 
 p53 plays a more central role in the surveillance of gene 
amplifications, abnormal recombination processes and the control over 
ploidy. 
 The function of p53 is critical to the way that many cancer treatment 
kill cells, since radiotherapy and chemotherapy act in part by 
triggering cell suicide in response to DNA damage. So tumors that 
frequently contain p53 mutations often respond poorly to radiation or 
chemotherapy. 
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UPSTREAM         
p53 
 
p53 increased levels 
modification 
 
p53* (Active p53) 
DOWNSTREAM 
Direct Signalling    Transcriptional Activation 
Apoptosis 
    Cell cycle arrest    Apoptosis 
              Repair   Not possible 
 Due to above reasons, p53 is terms as "Guardian of Human 
Genome" or "Cellular Gatekeeper" (17). 
Sensor of DNA Damage 
  10
PURPOSE OF THE STUDY 
 This study is done to analyse the p53 status of our patients with 
esophageal and gastric malignancies. For planning a gene therapy, 
genetic assessment of the tumor is the mandatory entry criterion. 
 As most of these malignancies are diagnosed at advanced stage, 
curative therapy may not be possible in most of the situations and hence 
identification of mutant genes can help in genetically manipulating the 
tumor. 
 This will help us in identifying the patients who will respond to 
ionising radiation and in choosing appropriate chemotherapeutic agents. 
For example ESCCs expressing mutant p53 will have augmented 
response for vinorelbine, taxanes and irinotecan (31,45). This study will 
form the basis for initiating adenoviral vector mediated gene therapy. 
 The likely ways to increase p53 levels are by impairing Mdm2 
function and by inducing the accumulation of the p53 in the nucleus by 
nuclear export inhibitor  leptomycin B (LMB). 
 This study on p53 will be contributing new ideas to the 
development of novel non-genotoxic activators of p53 and stimulate 
researchers to keep on discovering new targets of the p53 pathway. 
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LACUNAE IN CURRENT KNOWLEDGE 
 Studies on mutant p53 analysis in esophageal and gastric 
malignancies principally come from Western World (2), Middle East 
(19), Japanese (26) and Chinese(1) subcontinents. There are not many 
studies from this part of India. It  is prudent to have a local data about 
expression of mutant p53 in our patients, so that a comparative analysis 
of etiological risk factors could be done. With the present multimodal 
therapy, the results obtained are not very effective and is principally 
palliative (30, 31). The modern therapies with adenoviral vector and other 
non-genotoxic agents have been promising in Japanese studies. 
 To give the benefit of these advanced therapies we need to have a 
base line data based on the Indian population. 
 The tumorigenesis of Esophageal and gastric malignancies is still 
elusive to the researchers. So far, the epidemiology has advanced to tell 
us about the possible association with smoking and ethanol usage  
(27, 42). But still there are patients who succumb to the type of 
malignancy without the above risk factors (23). Till date we are not in a 
position to explain the etiology for occurrence of malignancy in different 
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levels of esophagus and stomach. Understanding the molecular basis of 
these cancers will remove the lacunae in the current knowledge about 
these malignancies. 
 More closer look into the carcinogenesis is needed to identify other 
synergistic and dysynergistic factors which determine the tumor 
progression. 
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HYPOTHESIS 
 Cell cycle abnormalities are said to be the cause for initiation and 
maintenance of any malignancy. Normally several key proteins are 
essential for maintenance of this homology. When there is aberrance in 
expression of any of the key proteins, abnormal cell cycling sets in and 
malignancy ensures. Point mutations, occurring frequently in the gene 
coding for the p53 protein, results in the accumulation of mutant protein. 
India is experiencing one of the highest cancer incidence rates in the 
world for esophageal and gastric malignancy. We have attempted here to 
elucidate the mutant p53 status in these malignancies. 
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REVIEW OF LITERATURE 
 Early studies based on mutant p53 status in esophageal and gastric 
cancers dates back to 1990. 
• During Dec. 1990, the research team consisting of Holsteich MC  
et al., (36) of the international agency for research on cancer, cyon, 
france  published their work on this subject. They identified mutant 
p53 in one third of the ESCCs studied. They were the early team to 
sequence the p53 and studied about the mutational status in exon  
5-9. However, the study was not able to suggest further insight 
possibly due to technical limitations. 
• Meltzer S.J. et al., (37) from Univ of Maryland, Baltimore  
elucidated the loss of heterozygosily (LoH) affecting the chr. 17p. 
They established the allelic loss in nearly half of the tumors studied 
and hypothesised that inactivation of p53 was involved in the 
pathogenesis of ESCCs. 
• In 1994, Wang DY et al., (43) from Hamamatsu Medical School, 
Japan did a larger study from ESCC patients from the Linxian 
province of China, which still remains the endemic area. He related 
the accumulation of mutant p53 to the invasiveness and capability 
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for metastasis of cancer cells. He was amongst the early 
researchers to prognosticate ESCC patients with respect to mutant 
p53 expression. 
• In 1997, Annals of surgical oncology presented a publication by  
Baron PL (46) from Medical University of S. Carolina, Charleston, 
USA. He established the presence of p53 mutation on both ESCC 
tumor tissues and in other normal looking tissues. He concluded 
that they inherited a defect in the p53 expression. He again raised 
an important issue why esophagus is the targeted tissue when there 
is a generalized mutant p53 expression. The scientists at p53 lab, 
unit of carcinogenesis. International Agency for research on. 
Cancer, Lyon, France went into the molecular pathway of p53 
mechanism, from the eso. cancer cell lines. They were able to 
induce the malignancy in the natural tumor cells when they 
exposed the non-tumor esophageal mutant p53 expressing cells to 
genotoxic stress. 
• In 2001, Koide et al., (53) studied the co-expression of VEGF and 
p53 protein in ESCC. His results confirmed the association of the 
expression of mutant p53 with angiogenesis and distal metastasis in 
ESCC and established the role of VEGF in p53 associated 
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angiogenesis. Aloia et al., from Duke University Medical School, 
North Carolina, USA established the prognostic value of the p53, 
TGF - α in ESCC patients. Putz et al., based on his extensive study 
concluded "Although difficult because of the documented  
co-exposure to various life style risk factors in most patients of this 
series, the hypothesis is proposed that besides smoking and alcohol 
drinking the commonly consumed hot mate tea in this high risk 
area for ESCC is responsible this different pattern of TP 53 
mutations because of chronic hyperthermia, irritation and 
inflammation in the esophagus with an endogenous formation of 
radicals or carcinogenic factors that lead to a higher prevalence of 
transition mutations. 
• In 2002, Wys  P. et al., from the MRC Centre, South Africa and 
Shimada et al., (55) from Chiba University, Japan started the first 
human trials on Ad5 CMV - p53 based gene therapy. He conducted 
his trials safely without complications. He also presented the data 
based on serum p53 antibodies is ESCC patients. It was useful to 
detect esophageal cancer, identify those who will have early 
recurrence and those with poor prognosis. Simultaneously Raja  
et al., from Pittsburgh, USA published his review on tumor 
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suppressor genes in ESCC. He highlighted the accumulating 
knowledge about the inactivation of the TSG could ultimately 
provide us with objective diagnostic tools and information which 
will facilitate the researchers to work on novel therapeutic avenues. 
• In 2003, Zuo LF et al.,  (57) from the provincial tumor institute, 
Hebei province, China investigated the alteration of molecular 
events and the early carcinogenesis mechanism of esophageal 
epithelial cells. His data showed almost 100% mutant p53 
expression in the tissue studied from the endemic Hebei province. 
He used advanced DNA flow cytometry and correlated the DNA 
ploidy and various other TSG. He concluded increased DNA 
content and heteroploid rate, accumulation of p53 protein and over-
expression of p21, telomerase and cyclin D proteins were early 
molecular events during the development of esophageal cancer. 
• In 2003, Matsubara H (58) published the update from the ongoing 
therapy for advanced ESCC. He devised a newer protocol for 
improving the efficacy of gene therapy by using invivo 
electroporation. Moreover, electric pulse to established solid 
tumors increases intracellular concentrations of chemotherapeutic 
agents. He inferred electrochemo-gene therapy is a relatively 
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simple method and can produce a better therapeutic effect. Xing Y 
et al., published his famous study "Expressions of PCNA, p53, p21 
(WAF-1) and cell proliferation in fetal esophageal epithelia." 
Comparative study with adult esophageal lesions from subjects of 
high-incidence area for esophageal cancer in Henon, North China. 
He inferred that p53 may play an important role in growth and 
differentiation of fetal esophageal epithelium. 
  19
 
STUDY DETAILS 
Type of study  : Prospective descriptive experimental study 
Study Duration : January 2004 to December 2005 
 
Collaborating Institutions : 
1. Department of surgery, Government Royapettah Hospital, Kilpauk 
Medical College, Chennai -10, India. 
2. Division of immunohistochemistry, R & D path lab, Mylapore, 
Chennai, India. 
3. Department of Surgical, Gastro-enterology, Government 
Royapettah Hospital, Chennai - 14, India. 
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DETAILS OF MATERIAL AND EXPERIMENTAL 
DESIGN 
TISSUE SPECIMENS 
 Formalin fixed, paraffin embedded tissue from endoscopic biopsy 
of esophageal and gastric cancer patients were used for the study. 
Histological sections were studied by the collaborating pathologists at 
immuno histochemistry division of R & D Histopath Lab, Mylapore, 
Chennai. 
TECHNIQUE OF DETECTION 
 IHC is a multi-step procedure that requires specialised processing 
of the tissue, the selection of appropriate reagents and interpretation of 
the stained tissue sections. In general, IHC staining techniques allow for 
the visualisation of antigens by sequential application of a specific 
antibody to the antigen, a secondary antibody to the primary antibody, an 
enzyme complex and a chromogenic substrate. The enzymatic activation 
of the chromogen results in a visible reaction product at the antigen site. 
We have used this method in identifying mutant p53 in esophageal and 
gastric malignancies in our study. 
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MATERIALS AND METHODS 
 The primary antibody mouse anti-p53, clone-PAb 1801 was 
obtained from Zymed laboratories INC, South Sanfrancisco, CA 94080, 
USA. The necessary reagent, buffers, and humidifying chambers  
were utilised from the IHC division R & D histopath lab; Mylapore, 
Chennai-4. The primary monoclonal antibody is purified from mouse 
ascites and diluted in Phosphate buffered Saline (PBS), pH 7.4, and 1% 
bovine serum albumin (BSA) with 0.1% sodium azide (NaN3) as 
preservative. 
 Tissue section of 5 microns was cut with the help of Leica 
microtome. They were applied to Poly-L-Lysine precoated slides. The 
following staining protocol was followed. Dewaxing done in xylene bath 
& sections were brought to water through graded alcohol. They were 
subjected to microwave antigen retrieval in citrate buffer of pH 6 for  
30 mins. To block non-specific reactivity and staining from endogenous 
peroxidase, sections were incubated with hydrogen peroxide for  
5 minutes. 
 After rinsing, the slides were incubated at room temperature with 
p53 protein primary antibody for 1½ hrs. The slides were washed and 
biotinylated link was applied and incubated for 30 minutes. The sections 
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were incubated in biotinylated streptavidin HRP for 30 minutes. In 
between these stages, the slides were rinsed in 10 mm phosphate buffered 
saline. DAB, a substrate chromogen was applied and the slides were 
incubated for 5 minutes. The slides were thoroughly rinsed and 
counterstained with Mayer's Hematoxylin for 30 seconds and then 
covered with glycerol jelly and cover slip applied. 
 Throughout the procedure 98 to 100% humidity was maintained in 
a humid chamber. After the above procedure, the slides were ready for 
screening. 
 The IHC stained positive cells, look brown and negative cells look 
blue. 
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EVALUATION OF STAINING 
INTENSITY OF STAINING 
 The staining were graded as per the UICC guidelines. 
Grade 1  : Weak Staining (< 10%) 
Grade 2  : Staining in the peripheries alone (10 - 40%) 
Grade 3  : Intense staining in most of the tumor cells 
Grade 4  : Intense staining in all tumor cells. 
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DATA ANALYSIS 
STATISTICAL METHODS 
 The significance of the association between variables was tested by 
the χ2 test. The variables included in univariate statistical analysis were 
gender, age, degree of differentiation, location of the tumor, intensity of 
staining of mutant p53 protein. P values reported are for a two-sided test 
and the level of significance was set at 0.05. 
 SPSS version 14 software was used for the statistical analysis. This 
was done with help of the statistical analyst, the Institute of Social 
Paediatrics, Stanley Medical College, Chennai - 600 003. 
 The basic data collected during endoscopy regarding the age, sex, 
and the location of the tumor and degree of differentiation in the 
esophagus and stomach were analysed with regards to the staining of 
mutant p53 protein obtained after immunostaining. 
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STATEMENT OF LIMITATIONS 
 The study is based on a limited number of patients. A detailed 
study of more subjects and follow-up for a longer duration will augment 
the validity of the data. 
 The immunoexpression of mutant p53 comprises of all the 
mutations. To study the specific type of mutation, one needs to analyse 
the individual exon. Exon based analysis need more refined techniques in 
the form of PCR or DNA vector array. Use of these advanced tools will 
help one to locate the exact location and type of the mutation in the 
specific chromosome studied. 
ETHICAL ISSUES INVOLVED 
 The study was done in the tissue obtained from upper 
gastrointestinal endoscopy. No ethical conflicts are involved in the study. 
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PATIENT CHARACTERISTICS 
 n   =  80 
Characteristics    No. of Patients 
1. Gender 
 Carcinoma esophagus  =  55 
 Male     =  38 
 Female    =  17 
Carcinoma Stomach  =  25 
Male     =  18 
Female    =    7 
2. Age 
 Ca esophagus   =  30 - 87 years 
 Ca stomach    =  37 - 83 years 
3. Site 
 Ca Esophagus   =  55 
 Ca Stomach    =  25 
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4. HPE 
 Squamous Cell Carcinoma =  53 
 Adeno Carcinoma   =  27 
5. Differentiation 
 Ca esophagus 
 Well differentiated    = 20 
 Moderately differentiated = 15 
 Poorly differentiated  = 13 
 undifferentiated   =  7 
 
Ca Stomach 
Well differentiated   = 11 
Moderately differentiated = 10 
Poorly differentiated  =  4 
Undifferentiated   = 0 
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OBSERVATIONS 
AGE BASED OBSERVATION 
CARCINOMA ESOPHAGUS 
INTENSITY OF STAINING 
AGE 
0 1+ 2+ 3+ 4+ TOTAL PT TOTAL + 
30-40 0 1 0 4 2 7 7 
41-50 6 1 0 4 0 11 5 
51-60 8 1 3 2 3 17 9 
61-70 5 0 0 6 6 17 12 
71-80 0 1 0 0 1 2 2 
81-90 1 0 0 0 0 1 0 
TOTAL 20 4 3 16 12 55 35 
 
Age Total + Total - 
30-40 7 0 
41-50 5 6 
51-60 9 8 
61-70 12 5 
71-80 2 0 
81-90 0 1 
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 The above data was statistically analysed, Pearson Chi-square test  
χ2 = 9.66, P-value = 0.08. The study patients predominantly belonged to 
the 4th to 6th decade. The positivity was more appreciated in fifth and 
sixth decade. 
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AGE BASED OBSERVATION 
CARCINOMA STOMACH 
INTENSITY OF STAINING 
AGE 
0 1+ 2+ 3+ 4+ TOTAL PT TOTAL +
31-40 0 1 0 0 0 1 1 
41-50 4 2 0 0 0 6 2 
51-60 2 5 1 0 0 8 6 
61-70 1 2 0 0 0 3 2 
71-80 1 5 0 0 0 6 5 
81-90 1 0 0 0 0 1 0 
TOTAL 9 15 1 0 0 25 16 
 
Age Total + Total - 
31-40 1 0 
41-50 2 4 
51-60 6 2 
61-70 2 1 
71-80 5 1 
81-90 0 1 
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 The above data was statistically analysed, χ2 test = 6.19 and  
P-value = 0.28. The study patients predominantly belonged to the 4th to 
5th decade. The positivity was more appreciated in the fifth decade. 
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SEX BASED P53 STATUS 
ESOPHAGEAL CARCINOMA 
INTENSITY OF STAINING 
SEX 
0 1+ 2+ 3+ 4+ TOTAL PT TOTAL +
MALE 15 4 1 10 8 38 23 
FEMALE 6 0 2 5 4 17 11 
TOTAL 21 4 3 15 12 55 34 
 
 
 
 
 
 
 
 The above data was statistically analysed, χ2 test = 0.09,  
P-value = 0.77. The percentage of positivity of p53 had no difference 
among sexes in upper gastrointestinal malignancies.  
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SEX BASED p 53 STATUS 
 
CARCINOMA STOMACH 
INTENSITY OF STAINING 
SEX 
0 1+ 2+ 3+ 4+ TOTAL PT TOTAL +
MALE 8 10 0 0 0 18 10 
FEMALE 1 5 1 0 0 7 6 
TOTAL 9 15 1 0 0 25 16 
 
 
 
Sex Total + Total - 
MALE 10 8 
FEMALE 6 1 
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 The above data was statistically analysed, χ2 test = 0.90,  
P-value = 0.34. The percentage of positivity of p53 is more in females 
when compared to males.  
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ORGAN BASED p53 STATUS 
 
INTENSITY OF STAINING 
ORGAN 
0 1+ 2+ 3+ 4+ TOTAL PT TOTAL +
ESOPHAGUS 21 4 3 15 12 55 34 
STOMACH 9 15 1 0 0 25 16 
TOTAL 30 19 4 15 12 80 50 
 
 
ORGAN Total + Total - 
ESOPHAGUS 34 21 
STOMACH 16 9 
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 The above data was statistically analysed, χ2 test = 0.03,  
P-value = 0.85. The intensity of positivity is more in carcinoma 
esophagus.  
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HISTOPATHOLOGY BASED p53 STATUS 
 
CARCINOMA ESOPHAGUS 
HPE INTENSITY OF STAINING 
 0 1+ 2+ 3+ 4+ TOTAL PT TOTAL +
SCC 21 3 2 15 12 53 32 
ADENO CA 0 1 1 0 0 2 2 
TOTAL 21 4 3 15 12 55 34 
 
 
HPE Total + Total - 
SCC 32 21 
ADENO CA 2 0 
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 The above data was statistically analysed, χ2 test = 0.15,  
P-value = 0.70. There is no significant difference in positivity for both 
histopathological types in carcinoma esophagus.  
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HISTOPATHOLOGY BASED p53 STATUS 
 
CARCINOMA STOMACH 
INTENSITY OF STAINING 
HPE 
0 1+ 2+ 3+ 4+ TOTAL PT 
TOTAL 
+ 
ADENO 
CARCINOMA 9 15 1 0 0 25 16 
 
 
 
 
 
 
 
 
 p53 positivity is 64% in gastric carcinoma. 
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DIFFERENTIATION BASED p53 STATUS 
 
CARCINOMA ESOPHAGUS 
INTENSITY OF STAINING 
DIFFERENTIATION 
TYPE 
0 1+ 2+ 3+ 4+ TOTAL PT TOTAL +
WELL 
DIFFERENTIATED 8 1 2 4 5 20 12 
MOD. 
DIFFERENTIATED 4 0 0 8 3 15 11 
POORLY 
DIFFERENTIATED 5 2 1 2 3 13 8 
UNDIFFERENTIATED 4 1 0 1 1 7 3 
TOTAL 21 4 3 15 12 55 34 
 
 
DIFFERENTIATION TYPE Total + Total - 
WELL DIFFERENTIATED 12 8 
MOD. DIFFERENTIATED 11 4 
POORLY DIFFERENTIATED 8 5 
UNDIFFERENTIATED 3 4 
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 The above data was statistically analysed, χ2 test = 1.94,  
P-value = 0.59. There is no significant difference in positivity depending 
upon the differentiation of the tumor.  
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DIFFERENTIATION BASED p53 STATUS  
 
CARCINOMA STOMACH 
INTENSITY OF STAINING 
DIFFERENTIATION TYPE 
0 1+ 2+ 3+ 4+ TOTAL PT TOTAL +
WELL DIFFERENTIATED 4 6 1 0 0 11 7 
MOD. DIFFERENTIATED 3 7 0 0 0 10 7 
POORLY DIFFERENTIATED 2 2 0 0 0 4 2 
UNDIFFERENTIATED 0 0 0 0 0 0 0 
TOTAL 9 15 1 0 0 25 16 
 
DIFFERENTIATION Total + Total - 
WELL DIFFERENTIATED 7 4 
MOD. DIFFERENTIATED 7 3 
POORLY DIFFERENTIATED 2 2 
UNDIFFERENTIATED 0 0 
  43
 
 
 
 
 
 
 
 
 
 
 
 
 
 The above data was statistically analysed, χ2 test = 0.50,  
P-value = 0.77. p53 positivity is more in the poorly differentiated tumors.  
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DISCUSSION 
 Observation of this study and other similar studies 
Study Group Immuno-Positivity - p53 
Baron P.L. et al., (24, 46) 67% 
Kuwano et al., (66) 56% 
Coggi et al., (25) 55% 
Novoc et al., (26) 51% 
Okuda et al., (71) 75% 
Robert et al., (68) 84% 
Stephanie et al., (35) 70% 
Nan Hu et al., (65) 75% 
Miyata et al., (70) 72% 
Biramijamal et al., (19) 65% 
Mizobuclu et al., (67) 65% 
 
 The positive expression obtained in our study 64%, is comparable 
with Western, Japanese and middle east literature. The published 
literature have initially depended on IHC based detection of p53. As 
technology advanced, the recent research are based on PCR, Vector array 
mediated analysis, yeast cell culture assays. But the incidence of 
immunopositivity, 51-84% has been uniformly reproduced across various 
studies in esophageal and gastric cancer. The higher immunoexpression 
in few later studies might be due to the technical improvements in the 
detection methods. The possibility of unexplained factors controlling the 
expression of mutant p53 must be elucidated with more sophisticated 
diagnostic tools. 
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UNANSWERED QUESTIONS 
 In this study, p53 immunoreactivity was considered  to be 
attributable to the accumulation of abnormal p53 protein. Although this 
idea is generally accepted, we should remember that negative 
immunoreactivity of p53 does not always reflect normal p53 function, 
because there may be homozygous detection, stop codon mutation or 
acceleration of protein degradation. We do not know the type of mutation 
from the results obtained in this study. 
 In fact, a functional assay of p53 using fission yeast showed that 
70-90% of cancers display loss of the p53 function in various tumors, 
including SCC of the head and neck and uterus (59). In contrast, radiation 
therapy is clinically effective in more than half of these cancers (45). This 
strongly suggests the existence of an alternative pathway independent of 
p53, which regulates radiation sensitivity. The relationship between cell 
cycle and radiation effect is not fully understood. Prolonged cell cycle 
arrest is considered to induce terminal differentiation and loss of 
proliferative activity, and those cells would undergo cell death through a 
different mechanism from checkpoint. Detailed study of p53 in relation to 
the radiation and chemotherapy may assess this discrepancy in 
esophageal and stomach cancer. 
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 We are not able to establish from this study the real implication of 
the intensity of staining and role of p53 in the carcinogenesis. 
 The published data available do not explain the reason for the 
mutant p53 expression in various sites like esophagus and stomach. We 
feel that the coexisting risk factors also play a role in determining the 
location of the tumor. 
 Hence one should always keep in the mind regarding the 
possibility of a potent non-p53 based mechanism creating its control over 
the esophageal and gastric carcinogenesis. 
 The reagents and the primary antibody used in this study came 
from the western world. The expression of mutant p53 in our cancers may 
be different if we use the locally developed primary antibodies. 
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NEW QUESTIONS 
 It is evident from this study that the presence of mutant p53 
expression is almost 100% in the early onset cancers. Again a periodic 
p53 screening is mandatory in the patients who have the predilection and 
risk factors for the esophageal and gastric malignancies. Already research 
is on in analysing the expression of p53 in the fetal esophageal and 
gastric tissues. We do not know the role of p53 in the development of 
fetal esophagus and stomach. 
 In this study we are able to establish the presence of the mutant p53 
in the tumor tissue in about 64%. A detailed exon based analysis of 
mutations will help us to understand the above questions. So far we do 
not know about the existence of other factors which control the tumor 
pathway based on the type of mutations. We do not know whether there 
will be difference in the malignant cascade based on the type of 
mutations. 
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SUMMARY AND CONCLUSION 
 Esophageal cancer represents the third most common 
gastrointestinal malignancy and the gastric cancer remains second only to 
lung cancer as a leading cause of cancer mortality worldwide. Most of 
these cancers are advanced and often unresectable at diagnosis and 
resistant to chemotherapy. Recent advances in the world of molecular 
genetics have helped us in understanding the biology of the cancer  
(16, 17, 32, 33, 41). 
 p53 is an  important tumor suppressor gene, which plays a definite 
role in the upper gastro intestinal carcinogenesis (5-15, 24-36). We have 
done this study to elucidate the mutant p53 expression in upper gastro 
intestinal malignancies. The tissue obtained with endoscopic biopsy were 
utilised for this study. The histopathology was confirmed and typing was 
done. The tumor tissues were subjected to immunohistochemical 
examination for identification of mutant p53. The evaluations of the 
stained tissue were based on the UICC guidelines. Data obtained were 
based on various parameters. Statistical analysis was done before the data 
interpretation. 
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 Of the 80 cases of upper gastro-intestinal malignancies, 55 were 
esophageal cancers and the remaining 25 were gastric malignancies. Of 
the 55 cases of esophageal SCC, 34 (61.8%) of them stained positive for 
mutant p53. Among the positive, 23 were male and 11 were female. Of 
the 25 cases of gastric malignancies, 16 (64%) of them stained positive 
for mutant p53. Among the positive, 10 were male and 6 were female. 
 81.8% of the patients with esophageal malignancy studied 
belonged to the age group of 41 to 70 yrs. 92% of the patients with gastric 
malignancy studied belonged to the age group of 41 to 80 yrs. Decade 
wise distribution was equally shared, except for the extremes. Expression 
of mutant p53 and intensity of staining were different in different sites. 
An alternative strategy should be searched for the patients who stain 
negative for mutant p53 as the clinical efficacy of the available therapy is 
not favourable for these patients. 
 Mutant p53 expression is closely associated with the 
carcinogenesis of upper gastro intestinal malignancy. Expression of p53 
and other apoptotic markers could be used as an important biological 
index for planning therapy. As the role of p53 expression and response to 
chemotherapy and ionising radiation is evident from the upcoming large 
trials, this identification of p53 will help us to segregate patients to 
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different multimodal therapy (30). This mutant p53 expression is clearly 
implicated for the prognosis of upper gastrointestinal malignancy patients 
(45). This will help us to understand the degree of efficacy of various  
therapies in our patients. Apoptosis promoters such as bortezomib are at 
the forefront of current clinical development. 
 Recombinant adenoviral vector mediated gene therapy for 
advanced upper gastrointestinal malignancies have been safely given and 
the response obtained are encouraging. A baseline data of the mutant p53 
expression is mandatory for planning gene therapy in our patients. We 
have established the presence a mutant p53 in about two-thirds of our 
patients. 
 With the available technology, the reason for the findings could not 
be explained properly. More detailed analysis, say in the form of 
mutational analysis based on the exon level will help us to understand the 
mutations in a better way. Mapping of the entire genome of these cancers 
will help us in elucidating the pathway of carcinogenesis. 
 This study and similar studies will probably form the basis for 
progression towards the recombinant viral vector mediated gene therapy. 
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CUMULATIVE RESULTS 
S.No. PATIENT ENDOSCOPY  I/D AGE SEX SITE OF BIOPSY HPE DIFFERENTIATION     p53 GRADING 
1 442/04 52 M STOMACH ADENO CA Poorly Differentiated NEGATIVE   
2 404/04 83 M STOMACH  ADENO CA Well Differentiated NEGATIVE   
3 380/04 67 F STOMACH  ADENO CA Moderately Differentiated NEGATIVE   
4 284/04 65 M STOMACH  ADENO CA Moderately Differentiated POSITIVE 1+ 
5 277/04 45 M STOMACH  ADENO CA Moderately Differentiated NEGATIVE   
6 347/04 59 F STOMACH  ADENO CA Well Differentiated POSITIVE 2+ 
7 375/04 37 F STOMACH ADENO CA Moderately Differentiated POSITIVE 1+ 
8 295/04 73 M STOMACH ADENO CA Well Differentiated NEGATIVE   
9 231/04 64 M STOMACH  ADENO CA Moderately Differentiated POSITIVE 1+ 
10 111/04 52 M STOMACH ADENO CA Well Differentiated POSITIVE 1+ 
11 220/04 55 M STOMACH ADENO CA Well Differentiated NEGATIVE   
12 180/04 41 M STOMACH  ADENO CA Moderately Differentiated NEGATIVE   
13 75/04 75 M OG JN ADENO CA Poorly Differentiated POSITIVE 1+ 
14 66/04 75 F STOMACH  ADENO CA Poorly Differentiated POSITIVE 1+ 
15 120/04 58 F STOMACH  ADENO CA Moderately Differentiated POSITIVE 1+ 
16 56/04 50 M STOMACH  ADENO CA Well Differentiated POSITIVE 1+ 
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S.No. PATIENT ENDOSCOPY  I/D AGE SEX SITE OF BIOPSY HPE DIFFERENTIATION     p53 GRADING 
17 39/04 75 M STOMACH  ADENO CA Well Differentiated POSITIVE 1+ 
18 105/04 42 M STOMACH  ADENO CA Moderately Differentiated POSITIVE 1+ 
19 253/04 51 M STOMACH ADENO CA Moderately Differentiated POSITIVE 1+ 
20 182/04 76 F STOMACH  ADENO CA Well Differentiated POSITIVE 1+ 
21 358/04 79 M STOMACH  ADENO CA Well Differentiated POSITIVE 1+ 
22 612/04 50 M STOMACH  ADENO CA Well Differentiated NEGATIVE   
23 161/04 47 M STOMACH ADENO CA Poorly Differentiated NEGATIVE   
24 112/04 76 M STOMACH ADENO CA Poorly Differentiated POSITIVE 1+ 
25 610/04 59 M STOMACH ADENO CA Well Differentiated POSITIVE 1+ 
26 606/04 58 F STOMACH ADENO CA Moderately Differentiated POSITIVE 1+ 
27 584/04 55 F OG JN  ADENO CA Well Differentiated POSITIVE 2+ 
28 521/04 60 M ESOPHAGUS SCC Well Differentiated NEGATIVE   
29 467/04 65 F ESOPHAGUS SCC Poorly Differentiated POSITIVE 4+ 
30 472/04 55 M ESOPHAGUS SCC Poorly Differentiated POSITIVE 3+ 
31 545/04 40 M ESOPHAGUS SCC Undifferentiated POSITIVE 3+ 
32 57/04 72 M ESOPHAGUS SCC Well Differentiated POSITIVE 4+ 
33 521/04 50 F ESOPHAGUS SCC Poorly Differentiated NEGATIVE   
34 481/04 62 M ESOPHAGUS SCC Poorly Differentiated POSITIVE 4+ 
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S.No. PATIENT ENDOSCOPY  I/D AGE SEX SITE OF BIOPSY HPE DIFFERENTIATION     p53 GRADING 
35 470/04 41 M ESOPHAGUS SCC Well Differentiated NEGATIVE   
36 531/04 65 M ESOPHAGUS SCC Undifferentiated NEGATIVE   
37 16/05 48 F ESOPHAGUS SCC Poorly Differentiated NEGATIVE   
38 22/05 50 F ESOPHAGUS SCC Moderately Differentiated POSITIVE 3+ 
39 192/05 55 F ESOPHAGUS SCC Well Differentiated POSITIVE 2+ 
40 584/05 68 M ESOPHAGUS SCC Moderately Differentiated POSITIVE 3+ 
41 05/05 65 M ESOPHAGUS SCC Poorly Differentiated POSITIVE 4+ 
42 49/05 62 F ESOPHAGUS SCC Well Differentiated POSITIVE 3+ 
43 479/05 49 M ESOPHAGUS SCC Well Differentiated POSITIVE 3+ 
44 24/05 55 M ESOPHAGUS SCC Poorly Differentiated NEGATIVE   
45 371/05 47 M ESOPHAGUS SCC Poorly Differentiated NEGATIVE   
46 392/05 56 M ESOPHAGUS SCC Moderately Differentiated POSITIVE 4+ 
47 56/05 61 M ESOPHAGUS SCC Moderately Differentiated POSITIVE 3+ 
48 104/05 40 M ESOPHAGUS SCC Poorly Differentiated POSITIVE 3+ 
49 39/05 70 F ESOPHAGUS SCC Well Differentiated POSITIVE 3+ 
50 253/05 50 M ESOPHAGUS SCC Moderately Differentiated POSITIVE 3+ 
51 182/05 53 F ESOPHAGUS SCC Well Differentiated NEGATIVE   
52 358/05 53 F ESOPHAGUS SCC Well Differentiated NEGATIVE   
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S.No. PATIENT ENDOSCOPY  I/D AGE SEX SITE OF BIOPSY HPE DIFFERENTIATION     p53 GRADING 
53 161/05 55 M ESOPHAGUS SCC Poorly Differentiated POSITIVE 2+ 
54 112/05 68 F ESOPHAGUS SCC Well Differentiated NEGATIVE   
55 612/05 45 M ESOPHAGUS SCC Moderately Differentiated NEGATIVE   
56 610/05 50 M ESOPHAGUS SCC Undifferentiated POSITIVE 1+ 
57 328/05 52 M ESOPHAGUS SCC Undifferentiated NEGATIVE   
58 66/05 55 M ESOPHAGUS SCC Undifferentiated NEGATIVE   
59 111/05 60 M ESOPHAGUS SCC Well Differentiated POSITIVE 1+ 
60 75/05 66 F ESOPHAGUS SCC Moderately Differentiated POSITIVE 4+ 
61 347/05 35 M ESOPHAGUS SCC Moderately Differentiated POSITIVE 3+ 
62 180/05 40 M ESOPHAGUS SCC Poorly Differentiated POSITIVE 1+ 
63 220/05 60 M ESOPHAGUS SCC Well Differentiated POSITIVE 4+ 
64 347/05 58 M ESOPHAGUS SCC Well Differentiated NEGATIVE   
65 277/05 60 M ESOPHAGUS SCC Moderately Differentiated POSITIVE 4+ 
66 404/05 45 F ESOPHAGUS SCC Well Differentiated NEGATIVE   
67 442/05 50 M ESOPHAGUS SCC Moderately Differentiated NEGATIVE   
68 380/05 70 M ESOPHAGUS SCC Moderately Differentiated NEGATIVE   
69 545/05 53 F ESOPHAGUS SCC Well Differentiated POSITIVE 3+ 
70 521/05 60 M ESOPHAGUS SCC Moderately Differentiated NEGATIVE   
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S.No. PATIENT ENDOSCOPY  I/D AGE SEX SITE OF BIOPSY HPE DIFFERENTIATION     p53 GRADING 
71 504/05 40 F ESOPHAGUS SCC Well Differentiated POSITIVE 4+ 
72 509/05 30 F ESOPHAGUS SCC Undifferentiated POSITIVE 4+ 
73 480/05 63 M ESOPHAGUS SCC Moderately Differentiated POSITIVE 3+ 
74 499/05 65 M ESOPHAGUS SCC Well Differentiated POSITIVE 4+ 
75 487/05 65 M ESOPHAGUS SCC Poorly Differentiated NEGATIVE   
76 481/05 87 M ESOPHAGUS SCC Undifferentiated NEGATIVE   
77 472/05 62 M ESOPHAGUS SCC Well Differentiated NEGATIVE   
78 470/05 68 F ESOPHAGUS SCC Moderately Differentiated POSITIVE 3+ 
79 388/05 40 M ESOPHAGUS SCC Moderately Differentiated POSITIVE 3+ 
80 467/05 68 M ESOPHAGUS SCC Well Differentiated POSITIVE 4+ 
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STUDY FORMAT 
 
Name  : 
Age  : 
Sex  : 
 a. Male 
 b. Female 
Patient Endoscopy ID No. 
Location of the tumor 
 a. Esophagus 
 b. OG Junction 
 c. Stomach 
Histopathology of the tumor 
 Adenocarcinoma 
 Squamous cell Carcinoma 
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Degree of Differentiation 
 a. Well Differentiated 
 b. Moderately Differentiated 
 c. Poorly Differentiated 
 d. Undifferentiated 
Immunohistochemistry 
 a. Positive 
 b. Negative 
Degree of Staining 
 a. Grade 1+ 
 b. Grade 2+ 
 c. Grade 3+ 
 d. Grade 4+ 
